A Phase II Clinical Trial of TQC3721 Suspension for Inhalation
Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
TQC3721 suspension for inhalation is a PDE3/4 inhibitor developed by Chia Tai Tianqing
Pharmaceutical Group Co., LTD., which can simultaneously achieve bronchial smooth muscle
relaxation and anti-inflammatory effects. This is a randomized, double-blind,
placebo-parallel, phase II trial of the efficacy and safety of inhaled TQC3721
suspension/placebo at different doses in patients with moderate to severe chronic obstructive
pulmonary disease. Objective To evaluate the efficacy, safety and tolerability of TQC3721
inhalation suspension in the treatment of moderate to severe Chronic Obstructive Pulmonary
Disease (COPD).